INY-03-041 emerges as a potent and highly selective pan-AKT degrader utilizing the PROTAC approach. This compound comprises the ATP-competitive AKT inhibitor Ipatasertib linked to Lenalidomide. With its inhibitory action, INY-03-041 effectively targets and suppresses AKT1, AKT2, and AKT3.
Usually ships within 24 hours.